Covered recipient · General Payments record
LANCE I KORTESOJA
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2021–2024
$1,955.20
- Reported across 98 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $622.48 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $222.38 | 12 |
| ABBVIE INC. | $87.55 | 5 |
| Novo Nordisk AS | $67.43 | 3 |
| Abbott Laboratories | $42.47 | 2 |
| Gilead Sciences, Inc. | $38.82 | 2 |
| Amgen Inc. | $32.42 | 2 |
| ITI, Inc. | $30.41 | 2 |
| Merck Sharp & Dohme Corporation | $27.87 | 1 |
| Averitas Pharma Inc. | $23.88 | 1 |
| Biogen, Inc. | $18.43 | 1 |
| Exact Sciences Corporation | $17.43 | 1 |
| GlaxoSmithKline, LLC. | $13.39 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $18.15 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124852552 | CMS |
| Abbott Laboratories | $24.32 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124852554 | CMS |
| ABBVIE INC. | $20.88 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107482331 | CMS |
| ABBVIE INC. | $14.03 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107482333 | CMS |
| ABBVIE INC. | $15.63 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107482335 | CMS |
| ABBVIE INC. | $20.88 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107482337 | CMS |
| ABBVIE INC. | $16.13 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107482339 | CMS |
| Amgen Inc. | $17.32 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117300795 | CMS |
| Amgen Inc. | $15.10 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117601697 | CMS |
| Averitas Pharma Inc. | $23.88 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133462934 | CMS |
| Biogen, Inc. | $18.43 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104863992 | CMS |
| Exact Sciences Corporation | $17.43 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114740633 | CMS |
| Gilead Sciences, Inc. | $18.97 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133718287 | CMS |
| Gilead Sciences, Inc. | $19.85 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133718289 | CMS |
| GlaxoSmithKline, LLC. | $13.39 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116582777 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.76 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143528135 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.65 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143528137 | CMS |
| Merck Sharp & Dohme LLC | $27.87 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141828738 | CMS |
| Novo Nordisk Inc | $22.32 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100343676 | CMS |
| Novo Nordisk Inc | $24.96 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100237604 | CMS |
| Novo Nordisk Inc | $20.15 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100317872 | CMS |
| PFIZER INC. | $20.30 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131163382 | CMS |
| PFIZER INC. | $20.46 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131039741 | CMS |
| PFIZER INC. | $19.76 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131609626 | CMS |
| PFIZER INC. | $18.37 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131280224 | CMS |
| PFIZER INC. | $5.71 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131609637 | CMS |
| PFIZER INC. | $22.06 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131455426 | CMS |
| PFIZER INC. | $19.56 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131609633 | CMS |
| PFIZER INC. | $18.62 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131609630 | CMS |
| PFIZER INC. | $17.85 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131609641 | CMS |
| PFIZER INC. | $22.90 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131975341 | CMS |
| PFIZER INC. | $17.83 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131162221 | CMS |
| PFIZER INC. | $18.96 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131060351 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.